Orphan drugs and the NHS: fairness in health care entails more than cost effectiveness.
Sheehan
Mark
M
D003362:Cost-Benefit Analysis; D006801:Humans; D009965:Orphan Drug Production / Q000191:economics*; D035583:Rare Diseases / Q000188:drug therapy*; D013222:State Medicine / Q000191:economics; D006113:United Kingdom